|
JP3415145B2
(ja)
|
1991-03-05 |
2003-06-09 |
ザ ウエルカム ファウンデーション リミテッド |
弱毒化細菌における組換えタンパク質の発現
|
|
US5962406A
(en)
|
1991-10-25 |
1999-10-05 |
Immunex Corporation |
Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
|
|
US7405270B2
(en)
|
1991-10-25 |
2008-07-29 |
Immunex Corporation |
CD40-Ligand lacking native-pattern glycosylation
|
|
KR100283541B1
(ko)
|
1991-10-25 |
2001-03-02 |
크리스토퍼 엘. 와이트, 스코트 지. 홀퀴스트, 스티븐 엘. 말라스카 |
신규 사이토킨
|
|
US5981724A
(en)
|
1991-10-25 |
1999-11-09 |
Immunex Corporation |
DNA encoding CD40 ligand, a cytokine that binds CD40
|
|
EP0659086B1
(en)
|
1992-09-04 |
1998-11-11 |
The University of Saskatchewan |
Novel bacterial vaccines using vaccine strains of pathogenic bacteria
|
|
AU1059095A
(en)
|
1993-11-24 |
1995-06-13 |
Australian National University, The |
Treatment of viral disease with cd40l peptide
|
|
EP0812206B1
(en)
|
1995-03-01 |
2002-07-10 |
Immunex Corporation |
Cd40 binding protein for stimulating an immune response
|
|
ES2214541T3
(es)
|
1995-06-07 |
2004-09-16 |
Immunex Corporation |
Muteina de cd40l.
|
|
US6713279B1
(en)
|
1995-12-07 |
2004-03-30 |
Diversa Corporation |
Non-stochastic generation of genetic vaccines and enzymes
|
|
US6479258B1
(en)
|
1995-12-07 |
2002-11-12 |
Diversa Corporation |
Non-stochastic generation of genetic vaccines
|
|
US6306387B1
(en)
|
1997-05-29 |
2001-10-23 |
The Research Foundation Of State University Of New York |
Antigen delivery system
|
|
US20030045492A1
(en)
|
1997-08-13 |
2003-03-06 |
Tang De-Chu C. |
Vaccination by topical application of recombinant vectors
|
|
US6969609B1
(en)
|
1998-12-09 |
2005-11-29 |
The United States Of America As Represented By The Department Of Health And Human Serivces |
Recombinant vector expressing multiple costimulatory molecules and uses thereof
|
|
CA2223225A1
(en)
|
1997-11-28 |
1999-05-28 |
Canadian Red Cross Society |
Method for inhibiting in vivo immune response
|
|
AU2004199A
(en)
|
1997-12-19 |
1999-07-12 |
Immunex Corporation |
Method for reducing susceptibility to hiv infection
|
|
GB9806449D0
(en)
|
1998-03-25 |
1998-05-27 |
Peptide Therapeutics Ltd |
Attenuated bacteria useful in vaccines
|
|
US6190669B1
(en)
|
1998-05-13 |
2001-02-20 |
University Of Maryland, Baltimore |
Attenuated mutants of salmonella which constitutively express the Vi antigen
|
|
IT1299583B1
(it)
|
1998-05-19 |
2000-03-16 |
Vander Way Limited |
Uso di proteine hmg-i per la preparazione di medicamenti ad attivita' citotossica
|
|
DK1108034T3
(da)
|
1998-09-04 |
2008-11-10 |
Emergent Product Dev Uk Ltd |
Svækkede salmonella SPI2-mutanter som antigenbærere
|
|
US7300774B1
(en)
|
1999-12-09 |
2007-11-27 |
The Regents Of The University Of California |
Multimeric fusion proteins of the TNF superfamily ligands
|
|
AU3966200A
(en)
|
1999-04-16 |
2000-11-02 |
F. Hoffmann-La Roche Ag |
Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof
|
|
EP1067194A1
(en)
|
1999-04-16 |
2001-01-10 |
F. Hoffmann-La Roche Ag |
Vectors containing a gene coding for CD40 and/or CD40L under the control of a cytokine-inducible promoter which is a human acute phase amyloid A gene promoter. Methods for their production and uses thereof
|
|
AU1084901A
(en)
|
1999-10-14 |
2001-04-23 |
Martha S. Hayden-Ledbetter |
Dna vaccines encoding antigen linked to a domain that binds cd40
|
|
ES2222152T3
(es)
|
1999-12-28 |
2005-02-01 |
Akzo Nobel N.V. |
Vacuna con las salmonellas que no inducen anticuerpos que reaccionan con la flagelina o los flagelos.
|
|
US7371392B2
(en)
|
2000-02-02 |
2008-05-13 |
The United States Of America As Represented By The Department Of Health And Human Services |
Cd40 ligand adjuvant for respiratory syncytial virus
|
|
DE60112413T2
(de)
|
2000-03-17 |
2006-06-01 |
Pharmacia & Upjohn Co. Llc, Kalamazoo |
Ssa inaktivierte salmonella impfstoffe
|
|
GB0015426D0
(en)
|
2000-06-24 |
2000-08-16 |
Univ Southampton |
Method for generating soluble highly multimeric proteins
|
|
US20030165538A1
(en)
|
2000-06-26 |
2003-09-04 |
Maxygen Incorporated |
Methods and compositions for developing spore display systems for medicinal and industrial applications
|
|
WO2002036769A2
(en)
|
2000-10-31 |
2002-05-10 |
F. Hoffmann-La Roche Ag |
Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof
|
|
CZ20033402A3
(cs)
|
2001-05-15 |
2004-10-13 |
Northáshore@Longáislandájewisháresearcháinstitute |
Použití fragmentů HMG jako protizánětlivých činidel
|
|
CA2447593C
(en)
|
2001-05-15 |
2014-07-08 |
Ortho-Mcneil Pharmaceutical, Inc. |
Ex-vivo priming for generating cytotoxic t lymphocytes specific for non-tumor antigens to treat autoimmune and allergic disease
|
|
US7220723B2
(en)
|
2001-05-15 |
2007-05-22 |
The Feinstein Institute For Medical Research |
Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
|
|
ITMI20011986A1
(it)
|
2001-09-25 |
2003-03-25 |
San Raffaele Centro Fond |
Metodo e composizione per l'attivazione di cellule presentanti l'antigene
|
|
DE50212280D1
(de)
|
2001-12-19 |
2008-06-26 |
Alcedo Biotech Gmbh |
Verwendung von hmgb-proteinen und dafür codierenden nukleinsäuren
|
|
US6923958B2
(en)
|
2002-03-02 |
2005-08-02 |
The Scripps Research Institute |
DNA vaccines encoding CEA and a CD40 ligand and methods of use thereof
|
|
EP1499191B1
(en)
|
2002-04-15 |
2012-05-09 |
Washington University in St. Louis |
Regulated attenuation of live vaccines to enhance cross protective immunogenicity
|
|
US7495090B2
(en)
|
2002-05-23 |
2009-02-24 |
The Regents Of The University Of California |
Nucleic acids encoding chimeric CD154 polypeptides
|
|
WO2004046338A2
(en)
|
2002-11-20 |
2004-06-03 |
North Shore-Long Island Jewish Research Institute |
Use of hmgb polypeptides for increasing immune responses
|
|
US20040141948A1
(en)
|
2002-11-20 |
2004-07-22 |
Critical Therapeutics, Inc. |
Use of HMGB fragments as anti-inflammatory agents
|
|
US20040156851A1
(en)
|
2002-11-20 |
2004-08-12 |
Critical Therapeutics, Inc. |
HMGB1 combination therapies
|
|
WO2004046345A2
(en)
|
2002-11-20 |
2004-06-03 |
Critical Therapeutics, Inc. |
Use of hmgb fragments as anti-inflammatory agents
|
|
US20060014248A1
(en)
|
2003-01-06 |
2006-01-19 |
Xencor, Inc. |
TNF super family members with altered immunogenicity
|
|
US20050181994A1
(en)
|
2003-01-06 |
2005-08-18 |
Xencor, Inc. |
Novel variants of CD40L protein
|
|
US7696169B2
(en)
|
2003-06-06 |
2010-04-13 |
The Feinstein Institute For Medical Research |
Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
|
|
US7754209B2
(en)
|
2003-07-26 |
2010-07-13 |
Trubion Pharmaceuticals |
Binding constructs and methods for use thereof
|
|
WO2005025604A2
(en)
|
2003-09-10 |
2005-03-24 |
The General Hospital Corporation |
Use of hmgb and hmgb fragments to decrease specific immune response
|
|
WO2005035570A2
(en)
|
2003-10-10 |
2005-04-21 |
Xencor, Inc. |
Variants of cd40l protein
|
|
EP1720905A2
(en)
|
2003-12-11 |
2006-11-15 |
Sidney Kimmel Cancer Center |
Methods for generating immunity to antigen
|
|
US8828957B2
(en)
|
2003-12-11 |
2014-09-09 |
Microvax, Llc |
Methods for generating immunity to antigen
|
|
JP2008508855A
(ja)
|
2004-04-27 |
2008-03-27 |
インターツェル・アクチェンゲゼルシャフト |
Ｔｄ抗原
|
|
WO2005113598A2
(en)
|
2004-05-21 |
2005-12-01 |
Xencor, Inc. |
Tnf super family members with altered immunogenicity
|
|
US20080305120A1
(en)
*
|
2004-06-17 |
2008-12-11 |
Medimmune, Inc. |
Immunogenic Compositions Comprising Hmgb 1 Polypeptides
|
|
US20080075728A1
(en)
|
2004-07-20 |
2008-03-27 |
Walter Newman |
Combination Therapies Of Hmgb And Complement Inhibitors Against Inflammation
|
|
EP1809737B9
(en)
|
2004-10-07 |
2011-10-05 |
Argos Therapeutics, Inc. |
Mature dendritic cell compositions and methods for culturing same
|
|
US8513008B2
(en)
|
2004-10-07 |
2013-08-20 |
Argos Therapeutics, Inc. |
Mature dendritic cell compositions and methods for culturing same
|
|
GB0423681D0
(en)
|
2004-10-26 |
2004-11-24 |
Sec Dep For Environment Food & |
Vaccine and nucleic acids
|
|
EP1831259A2
(en)
|
2004-12-21 |
2007-09-12 |
Vaxinnate Corporation |
Compositions of influenza viral proteins and methods of use thereof
|
|
WO2006105972A1
(en)
|
2005-04-07 |
2006-10-12 |
Universite Libre De Bruxelles |
Transgenic organism expressing cd40l and uses thereof
|
|
US20060286074A1
(en)
|
2005-05-31 |
2006-12-21 |
Yucheng Tang |
Methods for immunotherapy of cancer
|
|
WO2007011606A2
(en)
|
2005-07-18 |
2007-01-25 |
Critical Therapeutics, Inc. |
USE OF HMGBl ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY SKIN CONDITIONS
|
|
BRPI0616978A2
(pt)
|
2005-10-07 |
2011-07-05 |
Proyecto Biomedicina Cima Sl |
combinação imuno-estimulante para a profilaxia e tratamento de hepatite c, sua utilização, composição farmacêutica que a contém, kit para sua administração, método para produzir uma resposta imune e vacina contra o vìrus da hepatite c
|
|
AU2006311752A1
(en)
|
2005-11-07 |
2007-05-18 |
Sidney Kimmel Cancer Center |
CD40 ligand fusion protein vaccine
|
|
WO2007054658A1
(en)
|
2005-11-14 |
2007-05-18 |
King's College London |
Control of immune responses
|
|
WO2007130725A2
(en)
|
2006-02-06 |
2007-11-15 |
University Of Pittsburgh Of The Commonwealth System Of Higher Education |
Use of hmgb1 for protection against ischemia reperfusion injury
|
|
WO2007103048A2
(en)
|
2006-03-01 |
2007-09-13 |
Regents Of The University Of Colorado |
Tlr agonist (flagellin)/cd40 agonist/antigen protein and dna conjugates and use thereof for inducing synergistic enhancement in immunity
|
|
WO2007106073A2
(en)
|
2006-03-02 |
2007-09-20 |
University Of Massachusetts |
Modified pathogens for use as vaccines
|
|
US9439959B2
(en)
*
|
2006-07-27 |
2016-09-13 |
Takeda Vaccines, Inc. |
Chimeric influenza virus-like particles
|
|
US8564612B2
(en)
*
|
2006-08-04 |
2013-10-22 |
Apple Inc. |
Deep pixel pipeline
|
|
JP2010500034A
(ja)
*
|
2006-08-09 |
2010-01-07 |
メッドイミューン バクシーンズ，インコーポレイティド |
インフルエンザ赤血球凝集素変異体およびノイラミニダーゼ変異体
|
|
KR101460551B1
(ko)
*
|
2006-09-18 |
2014-11-18 |
더 보드 오브 트러스티스 오브 더 유니버시티 오브 아칸소 |
면역 반응을 향상시키는 조성물 및 방법
|
|
EP2139913A4
(en)
|
2007-03-08 |
2011-09-21 |
Mayo Foundation |
INTRODUCTION OF IMMUNE-MEDIUM TUMOR CELL DEOD
|
|
EP2152730A4
(en)
*
|
2007-05-02 |
2011-08-03 |
Univ Emory |
ENLARGEMENT OF GLYCOPROTEININCORPORATION IN VIRUSUAL PARTICLES
|
|
AU2008318615A1
(en)
|
2007-10-30 |
2009-05-07 |
Texas A&M University System |
Compositions and methods of enhancing immune responses to flagellated bacterium
|
|
CA2704422C
(en)
|
2007-11-01 |
2019-09-24 |
The Board Of Trustees Of The University Of Arkansas |
Compositions and methods of enhancing immune responses to eimeria
|
|
DK2525817T3
(en)
|
2010-01-21 |
2017-10-02 |
Univ Arkansas |
Vaccine vectors and methods for enhancing immune responses
|
|
NZ604412A
(en)
|
2010-06-09 |
2015-01-30 |
Univ Arkansas |
Vaccine and methods to reduce campylobacter infection
|
|
MX2014005754A
(es)
|
2011-11-11 |
2015-02-10 |
Nutrition Physiology Company Llc |
Bacterias de ácido láctico y su uso como suplementos dietéticos para aves de corral.
|